Liver transplantation for patients with colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the feasibility and outcomes of liver transplantation in patients with colorectal liver metastases (CLM), a condition previously deemed unsuitable for transplantation. The study aims to determine if advancements in surgical techniques and patient selection criteria can improve survival rates for these patients. Participants will be randomized to receive either liver transplantation or liver resection, with a focus on using extended criteria donors. The trial builds on previous findings that suggest improved long-term survival for selected patients with advanced CLM.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically verified adenocarcinoma in colon or rectum.
* No signs of extra hepatic metastatic disease or local recurrence according to PET/CT scan.
* No signs of extra hepatic metastatic disease or local recurrence according to CT or MR (thorax/abdomen/pelvis) scan within 4 weeks prior to the faculty meeting at the transplant unit
* No signs of local recurrence judged by colonoscopy / CT colography within 12 months prior to the faculty meeting at the transplant unit
* Good performance status, ECOG 0 or 1.
* Satisfactory blood tests Hb \>10g/dl, neutrophiles \>1.0 (after any G-CSF), TRC \>75, Bilirubin\<2 x upper normal level, ASAT,ALAT\<5 x upper normal level, ,Creatinine \<1.25 x upper normal level. Albumin above lower normal level.
* Standard surgical procedure with adequate resection margins including circumferential resection margins (CRM) of at least ≥2mm for rectal cancer patients.
* Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to GCP, and national/local regulations.
* Received at least 3 cycles of chemotherapy (6 weeks of treatment), with no increase in size of the lesions according to RECIST-criteria

Additional inclusion criteria for patients included in part A:

\- Six or more liver metastases technically resectable

Additional inclusion criteria for patients included in part B:

* Metachronous liver metastases (more than 12 months from diagnosis of CRC and/or end of adjuvant treatment)
* Pathological classification of primary tumor as pN0 disease.
* CEA\<100 ng/ml at time of primary diagnosis as well as at time of diagnosis of metastatic disease.
* Liver metastases not eligible for curative liver resection.
* Before start of 1. line chemotherapy, no lesion should be larger than 10 cm and total number of lesions should be 20 or less.
* At least 10% response (RECIST-criteria) on 1. line chemotherapy. Patients must be accepted for transplantation before progressive disease on 1. line chemotherapy.

Additional inclusion criteria for patients included in part C:

* Liver metastases not eligible for curative liver resection.
* Received 1.line treatment.
* Before start of 2. or 3. line chemotherapy, no lesion should be larger than 10 cm and total number of lesions should be 20 or less.
* At least 10% response (RECIST-criteria) on 2. or 3. line chemotherapy. Patients must be accepted for transplantation before progressive disease on 2. or 3. line chemotherapy.
* Two years or more time span from the CRC diagnosis and date of being listed on the transplantation list.

Additional inclusion criteria for patients included in part Arm D:

Patients with expected overall survival of 6-12 months without a liver transplant.

The patient might be included without further chemotherapy treatment. Patients may have resectable pulmonary lesions at time of inclusion in the present study.

Exclusion Criteria:

* Weight loss \>10% the last 6 months
* Patient BMI \> 30
* Other malignancies
* Prior extra hepatic metastatic disease or local relapse.
* Patients who have not received standard pre-operative, per-operative or post-operative treatment for the primary CRC.
* Palliative resection of primary CRC tumor.
* Previous randomization in this trial.
* Any reason why, in the opinion of the investigator, the patient should not participate.

Where it's running

• Oslo University Hospital
  Oslo, Norway Recruiting

Study contacts

• Study coordinator: Magnus Smedman, MD
• Email: torha@ous-hf.no
• Phone: 23026600

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liver transplantation for colorectal cancer with liver metastases

  This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.

  Recruiting Pontificia Universidad Catolica de Chile · Santiago, Santiago Metropolitan · NCT07884110

• Combining low dose radiotherapy with immunochemotherapy for colorectal cancer with liver metastasis

  This study is testing if combining low dose radiation with a specific chemotherapy can help people with colorectal cancer that has spread to the liver feel better and improve their treatment results.

  Recruiting Phase 1 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality and 1 other locations · NCT06848465

• Combining Fruquintinib, Regorafenib, and Sintilimab with Radiotherapy for Advanced Colorectal Cancer

  This study is testing a new combination of three cancer drugs with or without radiation to see if it helps people with advanced colorectal cancer who have already tried other treatments.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06356584

• Knife-assisted full-thickness resection for rectal lesions in a multicenter setting

  A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.

  Recruiting University Hospital, Ghent · Ghent · NCT07923682

• Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model

  This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.

  Recruiting Peking Union Medical College Hospital · Ningbo, Zhejiang · NCT07919418

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.